Table 3.
Patients characteristics
| |
Serum (training cohort) |
Serum (validation cohort) |
Tissue |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | LMP | Benign | Cancer | LMP | Benign | Cancer | LMP | Benign | |
| Patients |
53 |
18 |
57 |
16 |
5 |
21 |
40 |
20 |
24 |
| Age (years) |
59.2 (11.4) |
53.5 (10.3) |
56.6 (12.4) |
58.0 (14.8) |
43.3 (8.0) |
54.0 (14.5) |
55.8 (11.7) |
50.7 (10.3) |
53.4 (15.3) |
| BMI |
26.1 (5.4) |
28.7 (8.0) |
26.9 (6.0) |
26.5 (4.5) |
27.4 (5.8) |
26.6 (4.1) |
26.1 (4.5) |
28.8 (8.0) |
26.7 (5.0) |
| Premenopausal |
10 |
6 |
22 |
5 |
5 |
11 |
13 |
10 |
9 |
| Postmenopausal |
43 |
12 |
35 |
11 |
|
10 |
27 |
10 |
15 |
| Sample age (years) |
2.5 (0.9) |
2.3 (0.5) |
2.5 (0.6) |
0.7 (0.4) |
0.6 (0.2) |
1.7 (1.2) |
2.5 (1.2) |
2.5 (1.0) |
2.7 (0.9) |
| CA125 kU/L |
2451 |
63 |
42 |
5078 |
131 |
67 |
4117 |
89 |
26 |
| (range) |
(7–14100) |
(6–396) |
(1–164) |
(111–67448) |
(56–284) |
(2–312) |
(7–67448) |
(6–396) |
(5–164) |
|
Histological type |
|
|
|
|
|
|
|
|
|
| Serous |
38 |
13 |
|
13 |
3 |
|
32 |
6 |
|
| Mucinous |
5 |
5 |
|
1 |
2 |
|
2 |
14 |
|
| Endometrioid |
3 |
|
|
1 |
|
|
2 |
|
|
| Undifferentiated |
5 |
|
|
1 |
|
|
3 |
|
|
| Clearcell |
2 |
|
|
|
|
|
1 |
|
|
|
Grade |
|
|
|
|
|
|
|
|
|
| 1 |
2 |
|
|
|
|
|
2 |
|
|
| 2 |
12 |
|
|
3 |
|
|
9 |
|
|
| 3 |
39 |
|
|
12 |
|
|
29 |
|
|
| NA |
|
|
|
1 |
|
|
|
|
|
|
Figo Stage |
|
|
|
|
|
|
|
|
|
| I |
6 |
|
|
|
|
|
6 |
|
|
| II |
3 |
|
|
|
|
|
1 |
|
|
| III |
36 |
|
|
13 |
|
|
27 |
|
|
| IV | 8 | 3 | 6 | ||||||
Clinical and pathological characteristics of the three separate patient groups: cancer, low malignant potential (LMP) and benign tumor. The characteristics are given for the serum training, serum validation and tissue experiments. Age, body mass index (BMI) and sample age are given as a mean value with their standard deviation. In one patient differentiation grade was not available (NA).